Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21865648 | 0.91 | TERT (0.41) | CSNK2A2CSNK2BCSNK2A1ABCB1ABCC1 | |
| SCHEMBL22232647 | 0.91 | ABCB1 (0.45) | CSNK2A2CSNK2BCSNK2A1ABCB1ABCC1 | |
| SCHEMBL30744085 | 0.91 | SIGMAR1 (0.39) | CSNK2A2CSNK2BCSNK2A1SIGMAR1 | |
| SCHEMBL21801142 | 0.91 | SIGMAR1 (0.39) | CSNK2A2CSNK2BCSNK2A1SIGMAR1 | |
| SCHEMBL21801145 | 0.91 | SIGMAR1 (0.39) | CSNK2A2CSNK2BCSNK2A1SIGMAR1 | |
| SCHEMBL21801161 | 0.89 | SIGMAR1 (0.37) | CSNK2A2CSNK2BCSNK2A1ABCB1ABCC1 | |
| SCHEMBL30744132 | 0.88 | CSNK2A2 (0.36) | CSNK2A2CSNK2BCSNK2A1ABCB1ABCC1 | |
| SCHEMBL21801223 | 0.88 | CSNK2A2 (0.36) | CSNK2A2CSNK2BCSNK2A1ABCB1ABCC1 | |
| SCHEMBL22244939 | 0.85 | HPGD (0.39) | CSNK2A2CSNK2BCSNK2A1ABCB1ABCC1 | |
| SCHEMBL28610302 | 0.85 | HPGD (0.39) | CSNK2A2CSNK2BCSNK2A1ABCB1ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012390-B2 | Flavone compounds for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-112601743-B | Flavone compounds for the treatment and prevention of hepatitis b virus diseases | 豪夫迈·罗氏有限公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-3849966-B1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| EP-3849966-B1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20220363657-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-3849966-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| CN-112601743-A | Flavone compounds for treating and preventing hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2021-04-02 | — | — | CN | disclosed |
| WO-2020052774-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020052774-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020053249-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020053249-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012390-B2 | Flavone compounds for the treatment and prophylaxis of hepatitis B virus disease | PCNA, DNMT1, DNMT3B | CSNK2A2 3955/4885CSNK2B 3669/4885CSNK2A1 3802/4885 |
| US-20220363657-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | PCNA, DNMT1, DNMT3B | CSNK2A2 3955/4885CSNK2B 3669/4885CSNK2A1 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.